Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been assigned an average rating of “Buy” from the six brokerages that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $16.20.
Several equities research analysts have recently weighed in on REPL shares. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday, September 16th. JPMorgan Chase & Co. reduced their target price on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Barclays increased their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a research note on Thursday, June 6th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th.
Get Our Latest Stock Analysis on REPL
Replimune Group Price Performance
Replimune Group (NASDAQ:REPL – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Sell-side analysts forecast that Replimune Group will post -3.08 EPS for the current fiscal year.
Insider Transactions at Replimune Group
In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 20.60% of the company’s stock.
Institutional Trading of Replimune Group
A number of institutional investors have recently modified their holdings of REPL. Nisa Investment Advisors LLC raised its position in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the 2nd quarter valued at approximately $57,000. Quest Partners LLC purchased a new position in shares of Replimune Group in the 4th quarter valued at approximately $76,000. Diversified Trust Co purchased a new position in shares of Replimune Group in the 1st quarter valued at approximately $94,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
- Five stocks we like better than Replimune Group
- Investing in Construction Stocks
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Profitably Trade Stocks at 52-Week Highs
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.